{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:23:15Z","timestamp":1727410995626},"reference-count":35,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0174","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T10:03:17Z","timestamp":1727344997000},"source":"Crossref","is-referenced-by-count":0,"title":["The Long-term cure of patients with hereditary medullary thyroid carcinoma"],"prefix":"10.3238","author":[{"given":"Friedhelm","family":"Raue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bruckner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Frank-Raue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"10.3238\/arztebl.m2024.0174_ref1","doi-asserted-by":"crossref","unstructured":"Mathiesen JS, Kroustrup JP, Vestergaard P, et al.: Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960–2014: a nationwide study. Endocr Connect 2018; 7: 829–39.","DOI":"10.1530\/EC-18-0157"},{"key":"10.3238\/arztebl.m2024.0174_ref2","doi-asserted-by":"crossref","unstructured":"Gild ML, Clifton-Bligh RJ, Wirth LJ, Robinson BG: Medullary thyroid cancer: updates and challenges. Endocr Rev 2023; 44: 934–46.","DOI":"10.1210\/endrev\/bnad013"},{"key":"10.3238\/arztebl.m2024.0174_ref3","doi-asserted-by":"crossref","unstructured":"Engelbach M, Gorges R, Forst T, et al.: Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000; 85: 1890–4.","DOI":"10.1210\/jc.85.5.1890"},{"key":"10.3238\/arztebl.m2024.0174_ref4","doi-asserted-by":"crossref","unstructured":"Mathiesen JS, Effraimidis G, Rossing M, et al.: Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol 2022; 79: 163–79.","DOI":"10.1016\/j.semcancer.2021.03.035"},{"key":"10.3238\/arztebl.m2024.0174_ref5","doi-asserted-by":"crossref","unstructured":"Wells SA Jr., Asa SL, Dralle H, et al.: Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567–610.","DOI":"10.1089\/thy.2014.0335"},{"key":"10.3238\/arztebl.m2024.0174_ref6","doi-asserted-by":"crossref","unstructured":"Melvin KE, Miller HH, Tashjian AH Jr.: Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 1971; 285: 1115–20.","DOI":"10.1056\/NEJM197111112852004"},{"key":"10.3238\/arztebl.m2024.0174_ref7","doi-asserted-by":"crossref","unstructured":"Gagel RF, Tashjian AH Jr., Cummings T, et al.: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988; 318: 478–84.","DOI":"10.1056\/NEJM198802253180804"},{"key":"10.3238\/arztebl.m2024.0174_ref8","doi-asserted-by":"crossref","unstructured":"Donis-Keller H, Dou S, Chi D, et al.: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851–6.","DOI":"10.1093\/hmg\/2.7.851"},{"key":"10.3238\/arztebl.m2024.0174_ref9","doi-asserted-by":"crossref","unstructured":"Niccoli-Sire P, Murat A, Baudin E, et al.: Early or prophylactic thyroidectomy in MEN 2\/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur J Endocrinol 1999; 141: 468–74.","DOI":"10.1530\/eje.0.1410468"},{"key":"10.3238\/arztebl.m2024.0174_ref10","doi-asserted-by":"crossref","unstructured":"Machens A, Niccoli-Sire P, Hoegel J, et al.: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349: 1517–25.","DOI":"10.1056\/NEJMoa012915"},{"key":"10.3238\/arztebl.m2024.0174_ref11","doi-asserted-by":"crossref","unstructured":"Frank-Raue K, Buhr H, Dralle H, et al.: Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 2006; 155: 229–36.","DOI":"10.1530\/eje.1.02216"},{"key":"10.3238\/arztebl.m2024.0174_ref12","doi-asserted-by":"crossref","unstructured":"Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr.: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005; 353: 1105–13.","DOI":"10.1056\/NEJMoa043999"},{"key":"10.3238\/arztebl.m2024.0174_ref13","doi-asserted-by":"crossref","unstructured":"Torresan F, Censi S, Pennelli G, Galuppini F, Mian C, Iacobone M: Prophylactic and early thyroidectomy in RET germline mutation carriers in pediatric and adult population: long-term outcomes of a series of 63 patients. Cancers (Basel). 2022; 14: 6226.","DOI":"10.3390\/cancers14246226"},{"key":"10.3238\/arztebl.m2024.0174_ref14","doi-asserted-by":"crossref","unstructured":"Brandi ML, Gagel RF, Angeli A, et al.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658–71.","DOI":"10.1210\/jc.86.12.5658"},{"key":"10.3238\/arztebl.m2024.0174_ref15","doi-asserted-by":"crossref","unstructured":"Filetti S, Durante C, Hartl D, et al.: Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2019; 30: 1856–83.","DOI":"10.1093\/annonc\/mdz400"},{"key":"10.3238\/arztebl.m2024.0174_ref16","doi-asserted-by":"crossref","unstructured":"Binter T, Baumgartner-Parzer S, Schernthaner-Reiter MH, et al.: Does genotype-specific phenotype in patients with multiple endocrine neoplasia type 2 occur as current guidelines predict? Cancers (Basel). 2024; 16: 494.","DOI":"10.3390\/cancers16030494"},{"key":"10.3238\/arztebl.m2024.0174_ref17","doi-asserted-by":"crossref","unstructured":"Frank-Raue K, Rybicki LA, Erlic Z, et al.: Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 2011; 32: 51–8.","DOI":"10.1002\/humu.21385"},{"key":"10.3238\/arztebl.m2024.0174_ref18","doi-asserted-by":"crossref","unstructured":"Elisei R, Tacito A, Ramone T, et al.: Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes (Basel) 2019; 10: 698.","DOI":"10.3390\/genes10090698"},{"key":"10.3238\/arztebl.m2024.0174_ref19","doi-asserted-by":"crossref","unstructured":"Machens A, Elwerr M, Lorenz K, Weber F, Dralle H: Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations. Br J Surg 2018; 105: e150–e7.","DOI":"10.1002\/bjs.10746"},{"key":"10.3238\/arztebl.m2024.0174_ref20","doi-asserted-by":"crossref","unstructured":"Jung KY, Kim SM, Yoo WS, et al.: Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years. Clin Endocrinol (Oxf) 2016; 84: 587–97.","DOI":"10.1111\/cen.12852"},{"key":"10.3238\/arztebl.m2024.0174_ref21","doi-asserted-by":"crossref","unstructured":"Rohmer V, Vidal-Trecan G, Bourdelot A, et al.: Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d‘Etude des Tumeurs Endocrines. J Clin Endocrinol Metab 2011; 96: 509–18.","DOI":"10.1210\/jc.2010-1234"},{"key":"10.3238\/arztebl.m2024.0174_ref22","doi-asserted-by":"crossref","unstructured":"Lindsey SC, Ganly I, Palmer F, Tuttle RM: Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 2015; 25: 242–9.","DOI":"10.1089\/thy.2014.0277"},{"key":"10.3238\/arztebl.m2024.0174_ref23","doi-asserted-by":"crossref","unstructured":"Kluijfhout WP, van Beek DJ, Verrijn Stuart AA, et al.: Postoperative complications after prophylactic thyroidectomy for very young patients with multiple endocrine neoplasia type 2: retrospective cohort analysis. Medicine (Baltimore) 2015; 94: e1108.","DOI":"10.1097\/MD.0000000000001108"},{"key":"10.3238\/arztebl.m2024.0174_ref24","doi-asserted-by":"crossref","unstructured":"Elisei R, Romei C, Renzini G, et al.: The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab 2012; 97: 426–35.","DOI":"10.1210\/jc.2011-2046"},{"key":"10.3238\/arztebl.m2024.0174_ref25","doi-asserted-by":"crossref","unstructured":"Grubbs EG, Lechan RM, Edeiken-Monroe B, et al.: Hereditary endocrine tumours: Current state-of-the-art and research opportunities: early thyroidectomy in multiple endocrine neoplasia: a four decade experience. Endocr Relat Cancer 2020; 27: T1–T8.","DOI":"10.1530\/ERC-20-0108"},{"key":"10.3238\/arztebl.m2024.0174_ref26","doi-asserted-by":"crossref","unstructured":"Prete A, Gambale C, Torregrossa L, et al.: Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment. J Clin Endocrinol Metab 2023; 108: e613–e22.","DOI":"10.1210\/clinem\/dgad061"},{"key":"10.3238\/arztebl.m2024.0174_ref27","doi-asserted-by":"crossref","unstructured":"Saltiki K, Rentziou G, Stamatelopoulos K, et al.: Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur J Endocrinol 2014; 171: 117–26.","DOI":"10.1530\/EJE-14-0076"},{"key":"10.3238\/arztebl.m2024.0174_ref28","doi-asserted-by":"crossref","unstructured":"Spanheimer PM, Ganly I, Chou J, et al.: Long-term oncologic outcomes after curative resection of familial medullary thyroid carcinoma. Ann Surg Oncol 2019; 26: 4423–9.","DOI":"10.1245\/s10434-019-07869-9"},{"key":"10.3238\/arztebl.m2024.0174_ref29","doi-asserted-by":"crossref","unstructured":"Amin MB, Greene FL, Edge SB, et al.: The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more „personalized“ approach to cancer staging. CA Cancer J Clin 2017; 67: 93–9.","DOI":"10.3322\/caac.21388"},{"key":"10.3238\/arztebl.m2024.0174_ref30","doi-asserted-by":"crossref","unstructured":"Duval M, Ferreira CV, Marmitt L, et al.: An undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: results of a retrospective cohort study. Thyroid 2023; 33: 82–90.","DOI":"10.1089\/thy.2022.0295"},{"key":"10.3238\/arztebl.m2024.0174_ref31","doi-asserted-by":"crossref","unstructured":"Fanget F, Demarchi MS, Maillard L, Lintis A, Decaussin M, Lifante JC: Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Br J Surg 2021; 108: 1064–71.","DOI":"10.1093\/bjs\/znab106"},{"key":"10.3238\/arztebl.m2024.0174_ref32","doi-asserted-by":"crossref","unstructured":"Jin LX, Moley JF: Surgery for lymph node metastases of medullary thyroid carcinoma: a review. Cancer 2016; 122: 358–66.","DOI":"10.1002\/cncr.29761"},{"key":"10.3238\/arztebl.m2024.0174_ref33","doi-asserted-by":"crossref","unstructured":"Machens A, Lorenz K, Dralle H: Prediction of biochemical cure in patients with medullary thyroid cancer. Br J Surg 2020; 107: 695–704.","DOI":"10.1002\/bjs.11444"},{"key":"10.3238\/arztebl.m2024.0174_ref34","doi-asserted-by":"crossref","unstructured":"Raue F, Dralle H, Machens A, Bruckner T, Frank-Raue K: Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium. J Clin Endocrinol Metab 2018; 103: 235–43.","DOI":"10.1210\/jc.2017-01884"},{"key":"10.3238\/arztebl.m2024.0174_ref35","doi-asserted-by":"crossref","unstructured":"Machens A, Lorenz K, Brandenburg T, Fuhrer-Sakel D, Weber F, Dralle H: The changing face of multiple endocrine neoplasia 2A: from symptom-based to preventative medicine. J Clin Endocrinol Metab 2023; 108: e734–e42.","DOI":"10.1210\/clinem\/dgad156"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T10:03:36Z","timestamp":1727345016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":35,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0174","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}